Search the Newsreel

Quoin Pharmaceuticals | 10-Q: Quarterly report

This document is a quarterly report (10-Q) filed by Quoin Pharmaceuticals. It contains financial statements and other important disclosures required by the Securities and Exchange Commission for the reporting period.

Nicola Greenway (TAK) plans sale of 12,980 Takeda ADSs after RSU vesting

Nicola Greenway has filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, derived from vested Restricted Stock Unit Awards. The planned sale is scheduled for August 14, 2026, through Interactive Brokers LLC. This follows previous sales on August …

Syndax Pharmaceuticals (SNDX) Moved, What Is Behind The Fresh Attention?

Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals

Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax …

InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a 4.2% beneficial ownership stake in InMed Pharmaceuticals Inc. (INM), totaling 137,634 common shares. This ownership, held through Ikarian Healthcare Master Fund, L.P. and separately managed accounts, is based on 3,314,063 common shares outstanding as …

Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary

Processa Pharmaceuticals (PCSA) reported a net loss of $(3.27M) and diluted EPS of $(1.19) for the third quarter of 2026, showing an improvement from the previous year, with no product revenue. The company recently acquired Vidya, securing $200M in funding to advance new clinical …

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) reported a quarterly loss of $0.34 per share, beating analyst expectations by $0.05. Following the announcement, the stock rose 3.7% to $1.26. Analysts maintain a "Moderate Buy" rating with a $4.00 consensus price target, despite Oppenheimer lowering its target to $5.00.

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items. This …

Discipline and Rules-Based Execution in BCRX Response

This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for …

(AUPH) Risk Channels and Responsive Allocation

The article analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment despite potential long-term strength. It details an exceptional 43.3:1 risk-reward setup targeting an 11.7% gain versus 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles. The analysis includes …

Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock

Jennifer Lee, EVP of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), sold approximately $8.9 million worth of common stock after exercising options for about $997,036. The sale was executed under a Rule 10b5-1 trading plan as the stock trades near its 52-week high and is considered overvalued …

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for …

Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares

Jennifer Kayden Lee, EVP of Rhythm Pharmaceuticals (RYTM), exercised 56,601 stock options at prices of $24.29 and $6.80, and subsequently sold 75,834 common shares at $117.3818 per share. These transactions, valued at approximately $8.90 million gross proceeds from sales and $997K in exercise costs, …

Tonix Pharmaceuticals Holding Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNXP) 2026-08-14

Tonix Pharmaceuticals Holding Corp. (TNXP) has released its Q2 2026 earnings call presentation. The company reported an EPS of -$2.47, beating estimates by $0.15, and revenue of $13.54M, surpassing estimates by $5.82M with a 577.88% year-over-year increase. The slide deck provides details related to …

Eton Pharmaceuticals (ETON) Stock Reprices Higher After Profit Inflection

Eton Pharmaceuticals (ETON) stock surged 44.3% to US$58.86 after reporting a significant profit inflection in Q2 2026, with net income reaching US$11.6m and EPS of US$0.42 on US$37.6m revenue. This performance has led to increased revenue guidance for 2026 and supports the company's rare …

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements and concealed material adverse …

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential federal securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam significantly lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop …

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than …

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, …

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …

Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju have reported significant beneficial ownership in Eloxx Pharmaceuticals (ELOX). Dr. Srinivas Akkaraju holds 9.99% of the common stock, while each Samsara BioCapital-affiliated entity owns 5.0%. This includes common shares and Pre-Funded Warrants subject to a …

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported an 8.1% beneficial ownership stake in X4 Pharmaceuticals, Inc. This disclosure was made via an amended Schedule 13G filing, indicating shared voting and dispositive power over 8,085,006 shares, including …

Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts …

Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing (Form ARS) by Phio Pharmaceuticals Corp. (PHIO) on August 14, 2026. The filing has a low impact and neutral sentiment, and the document is available as a PDF. The article also provides recent news and other SEC …

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares

RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The …

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective …

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants

ADAR1 Capital Management, along with ADAR1 Capital Management GP, LLC and Daniel Schneeberger, have reported a beneficial ownership of 9.9% in Kiora Pharmaceuticals (KPRX). This stake, detailed in an amended passive investment disclosure (SCHEDULE 13G/A), includes common shares and shares underlying pre-funded and milestone …

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in Kiora Pharmaceuticals, Inc. (KPRX) through a Schedule 13G/A filing. As of June 30, 2026, they beneficially own 491,889 shares, including those acquirable through convertible …

Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 9.91% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. (ELOX) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially own 400,000 shares, with shared voting and …

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 2.07% on Friday, closing at $505.75, amid a general market decline where the S&P 500 and Dow Jones Industrial Average also saw losses. This marked the third consecutive day of losses for the company's shares.